Search This Blog

Thursday, May 1, 2025

Mercedes details plans for US production investments in Alabama

 Mercedes-Benz plans to begin producing a new vehicle at its Tuscaloosa, Alabama, plant in 2027, the company said Thursday, the latest in a series of investments carmakers have announced following U.S. President Donald Trump's aggressive auto tariffs.

The German automaker didn't disclose which vehicle it would add to its Tuscaloosa plant, only saying it would be a "core vehicle segment" that would "deepen its commitment to the U.S."

Trump's 25% levies on automotive imports have rocked the global automotive industry, although this week he offered a reprieve on some elements of the tariffs.

An analysis released by the Center for Automotive Research in early April found that the 25% auto tariffs would increase costs by about $108 billion for automakers in the U.S. in 2025.

Hyundai, GM and other automakers have boosted U.S. output or announced investments in response to the levies.

Mercedes this week pulled its earnings guidance amid tariff uncertainty. The automaker is facing hurdles in all its major markets, from Trump's tariffs, to competition from fast-moving rivals in China and new CO2 emissions targets in the European Union.

The company's Alabama plant currently produces the GLE, GLS, GLE Coupe, Mercedes-Maybach GLS, as well as the EQE SUV, EQS SUV, and Mercedes-Maybach EQS SUV for all global markets.

https://ca.finance.yahoo.com/news/mercedes-details-plans-us-production-151607664.html

Mahdawi accused of telling gun shop owner that he used to ‘kill Jews’ in Palestine: court docs

 Freed Palestinian Columbia University student Mohsen Mahdawi was once accused of telling a Vermont gun store owner that he used to “kill Jews while he was in Palestine” with modified automatic firearms that he built himself, court documents allege.

The allegations were laid bare in court papers filed Wednesday as the Trump administration unsuccessfully sought to keep Mahdawi in custody following his arrest for leading anti-Israel protests on the Ivy League campus.

In arguing its case, the Trump admin homed in on a visit Mahdawi made to the gun store in the summer of 2015, which resulted in the owner alerting local cops, the filing states.

Mohsen Mahdawi speaks outside the courthouse after his release on April 30, 2025.AP

“The gun shop owner told Windsor, Vermont, police officers that Mr. Mahdawi had visited his store twice, expressing an interest in learning more about firearms and buying a sniper rifle and an automatic weapon and that he ‘had considerable firearm experience and used to build modified 9mm submachine guns to kill Jews while he was in Palestine,'” the papers charge.

The owner also gave cops the name of another gun enthusiast who’d allegedly had a similar conversation with Mahdawi at a firearm museum where he volunteered.

In that exchange, the filing alleges the Columbia student said, “I like to kill Jews.”

Mahdawi, in his response, noted that he was interviewed by an FBI agent shortly after but denied making the remarks, the court papers state.

“Mahdawi confirmed that he had visited the gun shop and the Precision Museum but that he had never discussed buying weapons or killing Jews,” the filing notes.

Mohsen Mahdawi at a protest at Columbia University on Oct. 12, 2023.AP

He added that he’d visited the gun store to ask whether he needed to register a shotgun his then-wife had bought him.

Mahdawi is said to have told the agent he went to the museum because it was close to his house and he had an interest in machinery.

“Mr. Mahdawi states that the FBI agent was satisfied with his explanation and closed the investigation,” the docs state.

Mahdawi was released from custody Wednesday following an order from US District Judge Geoffrey Crawford.

Court filingDistrict of Vermont

Mahdawi, a legal permanent resident for 10 years, was arrested on April 14 during an interview about finalizing his US citizenship.

The State Department ultimately accused Mahdawi of engaging in “threatening rhetoric and intimidation” against Jewish students during Columbia protests.

Mahdawi’s lawyers argued he was detained in retaliation for his speech advocating for Palestinian human rights.

In his release order, the judge said Mahdawi had raised a “substantial claim that the government arrested him to stifle speech with which it disagrees.”

“Even if he were a firebrand, his conduct is protected by the First Amendment,” the judge wrote, adding that offending political opponents or alarming the State Department doesn’t make him dangerous enough to justify detention.

The Post reached out to Mahdawi’s attorney but didn’t immediately hear back.

https://nypost.com/2025/05/01/us-news/freed-columbia-university-student-mohsen-mahdawi-accused-of-telling-gun-shop-owner-that-he-used-to-kill-jews-in-palestine-court-docs/

"Extremely Bad Breach Of Ethics": Elon Musk Blasts Wall Street Journal's CEO Search Report

 Tesla Chairwoman Robyn Denholm denied a Wall Street Journal report claiming the board had begun searching for Elon Musk's successor, calling the story "absolutely false." Musk echoed the rebuke, slamming the story as an "EXTREMELY BAD BREACH OF ETHICS" by the legacy media outlet. 

"Earlier today, there was a media report erroneously claiming that the Tesla Board had contacted recruitment firms to initiate a CEO search at the company," Denholm wrote in a statement published on X via Tesla. 

She emphasized, "This is absolutely false (and this was communicated to the media before the report was published)," adding, "The CEO of Tesla is Elon Musk and the Board is highly confident in his ability to continue executing on the exciting growth plan ahead."

Musk chimed in, calling the WSJ story by Emily Glazer, Becky Peterson, and Dana Mattioli "an EXTREMELY BAD BREACH OF ETHICS that the WSJ would publish a DELIBERATELY FALSE ARTICLE and fail to include an unequivocal denial beforehand by the Tesla board of directors."

WSJ's Glazer and others cited anonymous sources to indicate that slumping vehicle sales and DOGE-related backlash had damaged the brand, prompting the board to search for a new CEO.

Here's an excerpt: 

Board members reached out to several executive search firms to work on a formal process for finding Tesla's next chief executive, according to people familiar with the discussions. 

... 

The board narrowed its focus to a major search firm, according to the people familiar with the discussions. The current status of the succession planning couldn't be determined. It is also unclear if Musk, himself a Tesla board member, was aware of the effort, or if his pledge to spend more time at Tesla has affected succession planning. Musk didn't respond to requests for comment.

Why WSJ's Glazer and her co-authors chose to publish the story—despite receiving a denial from Tesla's board before publication—underscores how legacy media spreads misinformation and disinformation.

This is the landscape Musk—and top officials in the Trump administration—are navigating: a hostile leftist corporate media environment that pushes endless streams of misinformation and disinformation.

Folks on X are saying...

*  *  *

https://www.zerohedge.com/markets/extremely-bad-breach-ethics-elon-musk-blasts-wall-street-journals-ceo-search

The Baby Hoax: Reporters Repeat False Narrative Over Child Deportations

 by Jonathan Turley,

For years, the mainstream media has been criticized for open political bias, including repeating false narratives and claims. 

There is little evidence that that will change despite falling revenues and audiences. 

That was evident this week as leading journalists continued to raise a dubious claim about the Trump Administration deporting children, including cancer patients.

The media has been promulgating a false claim that children as young as four are being deported.

The Administration immediately stated that the decision rested with the mothers on whether they would take the children or leave them in the United States with family.

Many of the same figures accused of promulgating false stories quickly picked up the spin from the Washington Post.

On NBC’s Meet the Press, Kristen Welker pursued the narrative with Secretary of State Marco Rubio:

KRISTEN WELKER: Let’s talk now about some new reporting that came in overnight. I want just to go through it with you and for our audience. Three U.S. citizen children have been deported with their mothers. Now this is according to The Washington Post. The family’s lawyer says one of them is a 4-year-old with Stage 4 cancer, deported without medication or ability to contact doctors. The family’s lawyers are also saying their clients were denied communication with family and legal representatives before being deported, and it’s raising concerns about the issue of due process. That it’s being violated. So let me ask you, is everyone on U.S. soil, citizens and non-citizens, entitled to due process?

MARCO RUBIO: Yes, of course. But let me tell you, it looks- in immigration standing, the laws are very specific. If you are in the country unlawfully, you have no right to be here and you must be removed. That’s what the law says. Somehow over the last 20 years, we’ve completely lost this notion that somehow- or completely adopted this idea that yes, we have immigration laws but once you come into our country illegally it triggers all kinds of rights that can keep you here indefinitely. That’s why we were being flooded at the border, and we’ve ended that. And that’s why you don’t- you see a historically low number of people not just trying to cross our border, trying to cross the border into Panama, all the way down in the Darien Gap. I mean- i it’s been a huge help for those countries as well. On the headline- that’s a misleading headline. Okay? Three U.S. Citizens, ages 4, 7 and 2 were not deported. Their mothers who were illegally in this country were deported. The children went with their mothers. Those children are U.S. citizens- they can come back into the United States- there’s- their father or someone here who wants to assume them. But ultimately who was deported was the mother- their mothers who were here illegally. The children just went with their mothers. But it wasn’t like- you guys make it sound like ICA agents kicked down the door and grabbed the 2 year-old and threw them on an airplane. That’s misleading. That’s just not true.

That would ordinarily leave a journalist looking at their shoes in embarrassment, but Welker decided to double down and add the claim that children are being denied “due process”:

WELKER: Just to be clear, because I do want to get to the overhaul at the State Department. Is it the U.S. policy to deport children, even U.S. citizens, with their families- and I hear what you’re saying- without due process? Just to be very clear there.

RUBIO: Well- no, no, no. No, no. Again, if someone is in this country unlawfully, illegally, that person gets deported. If that person is with a 2-year-old child or has a 2-year-old child and says “I want to take my child with you- with me,” well then you have two choices. You can say yes, of course, you can take your child whether they’re a citizen or not because it’s your child or you can say yes, you can go, but your child must stay behind. And then your headlines would read, “U.S. holding hostage 2-year old, 4-year-old, 7-year-old, while mother deported.”

There is a great deal of litigation working through the courts on the level of due process required for deportations. The public overwhelmingly supports the deportation of unlawful immigrants and elected Trump based on his pledge to carry out such deportations. Unlawful immigrants often spend years in this country despite orders of deportation or removal. The level of review depends on their status. If they have previously entered unlawfully, they are subject to expedited removal.

The critical point, however, is that the children are not being deported. 

If they were born in this country, they are still treated as U.S. citizens (though the Administration is challenging birthright citizenship in the courts).

Having a child in the United States does not make parents immune from removal or afford them special legal status over other deportees.

Over at CBS, Margaret Brennan (who was criticized for her “fact checks” in the presidential debate) also jumped on the narrative in interviewing Border Czar Tom Homan on Face the Nation:

MARGARET BRENNAN: On Friday, there were three American citizen children, born here, who were deported along with their mothers from Louisiana down to Honduras. And according to advocates, one of them is a 4-year-old child with Stage Four cancer. A rare form of metastatic cancer who was sent back to Honduras without getting to talk to a doctor and without medication. I understand this child’s mother entered this country illegally. But isn’t there some basis for compassionate consideration here that should have allowed for more consultation or treatment?

TOM HOMAN: Well, it certainly is discretionary. I’m not aware of this specific case. But no U.S. citizen child was deported. Deported means you gotta be ordered — reported by the immigration judge. We don’t deport U.S. citizens.

BRENNAN: The mother was deported along with the children.

HOMAN: These children- Children aren’t deported. The mother chose to take the children with her. When you enter the country illegally and you know you are here illegally and you choose to have a U.S. citizen child, that’s on you. That’s not on this administration. If you choose to put your family in that position, that’s on them. But having a U.S. citizen child, after you enter this country illegally, is not a “get out of jail free” card. It doesn’t make you immune from our laws. If that’s the message we send to the entire world, women are going to keep putting themselves at risk and come to this country. We send a message: you can enter the country illegally, that’s okay, you can have due process at great taxpayer expense, get ordered to move, that’s OK. Don’t leave, but have a U.S. citizen child and you are immune from removal? That’s not the way it works.

BRENNAN: So you don’t think there should be compassionate consideration for a 4-year-old child undergoing treatment for cancer?

HOMAN: I didn’t say that. I said ICE officers do have discretion-

BRENNAN: That was the question.

HOMAN: ICE officers do have discretion. I’m not familiar with the specific case. I don’t know what facts surround this case. I was just made aware of this when you mentioned it this morning. I was not aware of that case.

Brennan correctly noted that a court recently found a lack of due process in a child’s case. However, Holman had a reasonable response in citing the mother’s election in this one case to leave with her child.

BRENNAN: On Friday, a federal judge who was appointed by President Trump said a 2-year-old American citizen child had been sent to Honduras with the mother. But the judge said, quote: “there was no meaningful process.” So again, this is another similar situation and dynamic. Shouldn’t there be special care when the deportation cases involve small American-born children?

HOMAN: First of all, I disagree with the judge. There was due process. That female had due process at great taxpayer expense and was ordered by an immigration judge after those hearings. So she had due process. Again, this is Parenting 101. And you can decide to take that child with you or you can decide to leave the child here with a relative or another spouse. Having a child doesn’t make you immune from our laws of the country. American families get separated every day by law enforcement- thousands of times a day. When a parent gets put in jail, the child can’t go with them. If you are an illegal alien and you come to this country and you decide to have a U.S. citizen child, that’s on you. You put yourself in that position.

BRENNAN: Well, when it came to this particular case, you just pointed out that they could have made arrangements. The father tried, actually, to make arrangements as we understand it through our reporting. But he and the mother who were separated, since she was in detention after showing up for her appointment, was only allowed a very brief phone call. The father tried to petition to get the child handed over to an American citizen relative. So the mother had to make this decision and took the child with her. It just seems like there could be some more time frame here around due process allowed. That’s what the judge is saying, is saying- there should have been more of a process here.

HOMAN: There was due process. The 2-year-old baby- the two year old baby was left with the mother because the mother signed a document requesting her 2-year-old baby go with her. That’s the parent’s decision. I don’t think the judge knows the specifics of this case. The 2-year-old went with the mom. The mom signed a paper saying, “I want my 2-year-old to go with me.” That’s a parent’s decision. It’s not a government decision, it’s a parent’s decision.

BRENNAN: The father wrote a note. Anyhow, we have to leave it there, Director. Thank you for your time today. We’ll be right back.

It is important to note that these are two very different cases that were blended into the coverage.

In the second case, the government insists that there was no prior arrangement for the child to be left with the family and that the mother made this decision.

ICE should endeavor to accommodate such requests and there should always be an inquiry into allegations that these women were prevented from making arrangements for their children to remain in the country. However, there will also be practical limits in addressing those issues in the midst of a removal.

If Homan is correct, the mother was in the system long before the actual removal. The father “sending a note” at the end of that process is worth looking into, but it is hardly surprising that the removal proceeded with the mother’s consent.

The same narrative was playing over at ABC as Martha Raddatz had this exchange with former DoJ spokesperson Sarah Isgur:

MARTHA RADDATZ: Sarah, I want to turn here to some information that has been in The Washington Post about deportations of very young children who are American citizens. A 2-year-old, a 4-year-old, a 7-year-old sent back to Honduras. Is that legal?

SARAH ISGUR: This is something our immigration system deals with nearly every day. U.S. citizen children have to make that decision with their parents of whether they’re going to stay. The parent has the decision. We do not allow illegal alien parents to stay just because they have custody over U.S. citizen children, and at least one of these cases with the 2-year-old, the mother was the one who made the decision to take her daughter with her. The father is the one saying he wanted the daughter to stay here. Often times, it’s going to look more like a custody dispute than an immigration question.

Again, as Isgur correctly points out, this is the election of the parents who are being removed.

Critics have pushed back on these interviews, noting how the media seemed only marginally interested in thousands of children lost in the system under the Biden Administration as millions poured over the border.

The coverage suggested that children were being thrown on planes to be dumped in some foreign land.

The Washington Post, which is cited for the story, has been repeatedly accused of pushing misleading or false narratives. There was a recent riot in the newsroom when owner Jeff Bezos demanded that the newspaper return to more balanced coverage.

The most telling condemnation came from Post columnist Philip Bump, who wrote “what the actual f**k.” Bump has been repeatedly accused of false claims and previously had a meltdown in an interview when confronted about past false claims. After I wrote a column about the litany of such false claims, the Post surprised many of us by stating that it stood by all of Bump’s reporting, including false columns on the Lafayette Park protests, Hunter Biden’s laptop, and other stories. That was long after other media debunked the claims, but the Post stood by the false reporting.

We have previously discussed the sharp change in culture at the Post, which became an outlet that pushed anti-free speech views and embraced advocacy journalism. The result was that many moderates and conservatives stopped reading the newspaper.

In my book on free speech, I discuss at length how the Post and the mainstream media have joined an alliance with the government and corporations in favor of censorship and blacklisting. I once regularly wrote for the Post and personally witnessed the sharp change in editorial priorities as editors delayed or killed columns with conservative or moderate viewpoints.

Last year, that culture was vividly on display when the newspaper offered no objection or even qualification after its reporter, Cleve Wootson Jr., appeared to call upon the White House to censor the interview of Elon Musk with former President Donald Trump. Under the guise of a question, Wootson told White House Press Secretary Karine Jean-Pierre “I think that misinformation on Twitter is not just a campaign issue…it’s an America issue.”

The baby hoax shows that little has (or likely will) changed. In the meantime, the public is moving on. New media is rising as mainstream media audiences shrink. Journalists and columnists are increasingly writing for each other as polling shows trust in the media is at an all-time low.

Robert Lewis, a British media executive who joined the Post, reportedly got into a “heated exchange” with a staffer. Lewis explained that, while reporters were protesting measures to expand readership, the very survival of the paper was now at stake:

“We are going to turn this thing around, but let’s not sugarcoat it. It needs turning around,” Lewis said. “We are losing large amounts of money. Your audience has halved in recent years. People are not reading your stuff. Right. I can’t sugarcoat it anymore.”

It simply does not matter. The media continues to vigorously saw on the branch upon which it is sitting.

Jonathan Turley is the Shapiro professor of public interest law at George Washington University and the author of “The Indispensable Right: Free Speech in an Age of Rage.”

https://www.zerohedge.com/political/baby-hoax-reporters-repeat-false-narrative-over-child-deportations

GSK sets up Nucala and Dupixent showdown in COPD

 New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

The data from the MATINEE trial – published in the New England Journal of Medicine – reveal a 21% reduction compared to placebo in the annualised rate of moderate or severe exacerbations in a wide COPD population over 104 weeks of follow-up.

That comes in a little lower than the 30% and 34% reductions seen in two pivotal trials of Sanofi and Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab), which had its indications extended to include COPD last year, ending a 10-year drought in new COPD therapies and making it the first biologic therapy for the progressive respiratory disease.

GSK said, however, that MATINEE also revealed a 35% reduction in the annualised rate of exacerbations leading to an emergency department visit or hospitalisation with Nucala (mepolizumab). The result makes the antibody the only biologic showing that benefit in a phase 3 trial, albeit with a "nominally significant" difference to control.

In a statement, GSK pointed out that one in 10 patients who are hospitalised for COPD will die during the stay, rising to one in four over the next year, while half will lose their lives within five years. In the study, Nucala was added to inhaled maintenance therapy for COPD.

The antibody also showed a 31% reduction in the annualised rate of moderate/severe exacerbations versus placebo in a post-hoc analysis of patients with clinician-assessed chronic bronchitis only.

"Every physician will know the feeling of seeing a patient hospitalised due to an exacerbation that could have possibly been prevented," said MATINEE lead author Frank Sciurba of the University of Pittsburgh.

"The MATINEE trial uncovers new possibilities in the treatment landscape for COPD patients with type 2 inflammation, as we strive to target drivers of disease and improve the lives of patients suffering with COPD."

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium, and vilanterol) which was approved in 2018.

On GSK's first-quarter results call, chief commercial officer Luke Miels said he believes Nucala will be "very competitive" in COPD, in part because MATINEE included a wide spectrum of patients – with emphysema, combined emphysema and chronic bronchitis, and chronic bronchitis – making it an appealing option for physicians as "it can be difficult to stratify these patients at times."

He added that "about 83% of pulmonologists, when we show them the profile of the product, are very motivated to use Nucala in COPD."

Nucala is already approved for several indications, including eosinophilic asthma, and brought in £1.78 billion (around $2.4 billion) in sales last year. GSK has suggested that approval in COPD could drive sales above the £3 billion mark.

The company first tried to secure approval for Nucala in COPD several years ago, but the FDA was unmoved by mixed results in two other trials – METREX and METREO – and turned the application down in 2018.

COPD is the third leading cause of death worldwide, affecting more than 300 million people globally. Up to 40% of patients exhibit type 2 inflammation characterised by a raised blood eosinophil count, which would make them suitable for treatment with Nucala.

https://pharmaphorum.com/news/gsk-sets-nucala-and-dupixent-showdown-copd

J&J's 'Swiss army knife' drug gets first FDA approval

 Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for the would-be blockbuster as a treatment for generalised myasthenia gravis (gMG).

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the market – but J&J thinks the broad label for Imaavy (nipocalimab) will help it overtake its rivals.

It has billed Imaavy as the first FcRn blocker to be approved in anti-AChR and anti-MuSK antibody positive gMG patients aged 12 and older, saying that represents the "broadest population" of people living with the disease.

The indication covers more than 90% of the total antibody-positive population of gMG patients. The autoimmune muscle-wasting disease affects around 700,000 people worldwide and 100,000 in the US, according to J&J. It leads to symptoms like fatigue, muscle weakness, and respiratory and vision problems.

The company has also pointed to data showing durable, 20-month improvements in gMG symptoms – claiming that is the longest in the class and "translates into patients regaining essential daily functions, such as chewing, swallowing, speaking and breathing."

Imaavy will compete with Argenx's Vyvgart Hytrulo (efgartigimod alfa) and UCB's Rystiggo (rozanolixizumab) in gMG, both of which are administered by subcutaneous injection once a week, while Imaavy is given as an intravenous infusion every two weeks.

J&J has set a list price of $12,480 per vial for its drug, saying that it is "competitively priced" compared to the other FcRn blockers, but hasn't yet revealed a launch date. It has also launched a patient support programme – Imaavy withMe – to allow commercially-insured patients to receive the drug in as little as a week and in some cases with no co-pay.

J&J acquired nipocalimab when it bought Momenta Pharmaceuticals in 2020 for $6.5 billion, saying at the time that around 240 million people worldwide suffer from some form of auto-antibody-driven disease, many with no approved treatments.

It has previously suggested that the drug could eventually become a $5 billion-a-year product which, if achieved, would help it weather the impact of patent expiries on some of its biggest sellers, including immunology blockbuster Stelara (ustekinumab), which made more than $6.7 billion in US sales last year, but lost market exclusivity there at the start of this year.

For comparison, Argenx recorded $2.2 billion in sales of Vyvgart Hytrulo and its older IV version Vyvgart, while UCB booked just over $200 million from Rystiggo.

Development of Imaavy is also on the go in Sjogren's disease (SjD), rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIMs), chronic inflammatory demyelinating polyneuropathy (CIDP), haemolytic disease of the foetus and newborn (HFDN), warm autoimmune haemolytic anaemia (wAIHA), and paediatric gMG.

https://pharmaphorum.com/news/jjs-swiss-army-knife-drug-gets-first-fda-approval